Sch B Enhances the Sensitivity of Glioma to Temozolomide by Inducing Lethal Autophagy by Regulating the KCNB1/AMPK/mTOR Axis
Year: 2026
Type: article
Abstract: Schisandrin B (Sch B) is an active lignan derived from the Chinese herb Schisandra chinensis and exhibits multi-target anti-tumor activity. However, the mechanism and effect of Sch B in reversing temozolomide (TMZ) resistance in glioblastoma (GBM) remain unclear. In this study, through transcriptome screening, it was found that KCNB1 (Kv2.1) is the only common differentially expressed gene regulated by Sch B and TMZ alone or in combination. Database analysis revealed that its expression is downregulated in GBM and is closely related to poor prognosis and TMZ resistance in patients. In the TMZ-resistant cell line induced by U87, KCNB1 also shows a low expression level. The results of in vitro experiments indicated that the combined treatment of Sch B and TMZ can significantly upregulate KCNB1 and Kv2.1 expression and thereby regulate the AMPK/mTOR signaling axis (increased p-AMPK level and decreased p-mTOR level), induce lethal autophagy (increased LC3B-II/I ratio and increased p62 degradation), inhibit the proliferation of resistant cells, promote apoptosis, and restore TMZ sensitivity. Knockdown of KCNB1, the use of a Kv2.1-specific inhibitor, or the AMPK inhibitor Compound C can partially reverse these effects. The in vivo nude mouse xenograft tumor model further confirmed that the combined treatment can significantly inhibit tumor growth, upregulate the expression of KCNB1 in tumor tissues, activate the AMPK/mTOR pathway, and enhance autophagy levels. In summary, this study first reveals that Sch B upregulates KCNB1 to activate the AMPK/mTOR pathway and induces lethal autophagy, thereby reversing TMZ resistance in GBM, providing experimental evidence for the clinical application of Sch B as a TMZ sensitizer.
DOI: 10.3390/cimb48111237
Institutions: Jilin Medical University, Xi'an Jiaotong University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,654
Awards: G9001379402, G9001389327
OpenAlex ID: W7234610649
